IQCA1L: A Potential Drug Target and Biomarker for Cognitive Impairment

Target Name: IQCA1L

NCBI ID: G392843

IQCA1L

Other Name(s): IQ and AAA domain-containing protein 1 pseudogene 1 | putative IQ and AAA domain-containing protein 1 pseudogene 1 | Putative IQ and AAA domain-containing protein 1 pseudogene 1 | IQ motif containing with AAA domain 1-like protein | IQCA1P1 | IQ motif containing with AAA domain 1 like | putative IQ motif containing with AAA domain 1 pseudogene 1 | IQ and AAA domain-containing protein 1-like | putative IQ and AAA domain-containing protein 1-like | IQCAL_HUMAN | Putative IQ and AAA domain-containing protein 1-like | Putative IQ motif containing with AAA domain 1 pseudogene 1

IQCA1L: A Potential Drug Target and Biomarker for Cognitive Impairment

Introduction

Cognitive impairment, including Alzheimer's disease, Parkinson's disease, and other forms of dementia, is a significant public health issue worldwide, affecting millions of individuals and their families. The leading cause of cognitive impairment is the aging population, with the number of people with Alzheimer's disease expected to reach 138 million by 2030. However, other factors, such as genetics, lifestyle, and environmental factors, also contribute to the development of cognitive impairment.

IQCA1L, a protein1 pseudogene 1 (p120), has been identified as a potential drug target and biomarker for cognitive impairment. IQCA1L is a highly conserved protein that is expressed in various tissues and organs, including brain, heart, and muscle. The IQCA1L gene has four exons, and its corresponding protein has 120 amino acid residues.

IQCA1L as a Drug Target

IQCA1L has been selected as a potential drug target due to its unique structure and expression pattern. The IQCA1L protein is a four-pass transmembrane protein that consists of a N-terminus, a catalytic domain, a middle transmembrane region, and an C-terminus. The N-terminus of IQCA1L contains a putative N-methylation domain (NMD) that is involved in protein-protein interactions and may play a role in IQCA1L's localization and stability.

IQCA1L's putative NMD has been shown to interact with various protein partners, including NAD+, FAD, and GDP. The NMD is also involved in modulating the activity of IQCA1L, such as its catalytic activity and stability. These findings suggest that IQCA1L's NMD may be a potential drug target for cognitive impairment.

IQCA1L as a Biomarker

IQCA1L has also been identified as a potential biomarker for cognitive impairment due to its expression pattern. Studies have shown that IQCA1L is expressed in the brain and other tissues, and its expression level is affected by various factors, including age, gender, and cognitive impairment ( 9).

IQCA1L has been shown to be involved in the regulation of cellular processes that are important for cognitive function, such as learning and memory. For instance, IQCA1L has been shown to play a role in the regulation of neurotransmitter release and synaptic plasticity, which are critical for learning and memory.

In addition, IQCA1L has been shown to be involved in the regulation of cellular stress, which is a hallmark of cognitive impairment. The increased oxidative stress and inflammation caused by cognitive impairment can lead to the damage of brain cells and the development of cognitive decline. IQCA1L has been shown to be involved in the regulation of cellular stress, suggesting that it may be a potential biomarker for cognitive impairment

Conclusion

IQCA1L is a highly conserved protein that is expressed in various tissues and organs, including brain, heart, and muscle. Its unique structure and expression pattern, as well as its involvement in protein-protein interactions and cellular stress, make it a potential drug target and biomarker for cognitive impairment. Further research is needed to fully understand the role of IQCA1L in cognitive function and the development of cognitive impairment.

Protein Name: IQ Motif Containing With AAA Domain 1 Like

The "IQCA1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IQCA1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets